Physician profile
Mohammad Kamel Omari
NPI 1790715894
$6,752.56
in general payments reported to CMS, 2019-2025
29 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $202 · 2021: $365 · 2022: $1,027 · 2023: $1,160 · 2024: $1,712 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,672 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,672.08 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,701.72 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,485.65 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $448.36 | 2022-2025 | |
| Electromed, INC. | $376.68 | 2022-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $365.71 | 2019-2025 | |
| Insmed, INC. | $328.96 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $273.30 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $252.31 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.36 | 2021-2024 | Ofev |
| Amgen INC. | $213.45 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $186.76 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $161.73 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $113.84 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $102.81 | 2019-2023 | Zerbaxa, Dificid |
| Genentech USA, INC. | $83.64 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $78.73 | 2023-2025 | Lumryz |
| Pulmonx Corporation | $62.37 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Sanofi-Aventis U.S. LLC | $57.48 | 2024 | |
| Mallinckrodt Hospital Products INC. | $38.11 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $33.04 | 2022-2023 | Airduo Digihaler |
| Takeda Pharmaceuticals U.S.A., INC. | $32.21 | 2024-2025 | Glassia |
| Novartis Pharmaceuticals Corporation | $24.79 | 2019 | |
| Verona Pharma, INC. | $21.57 | 2025 | Ohtuvayre |
| Circassia INC. | $17.81 | 2019 | |
| Chiesi USA, INC. | $16.66 | 2019 | |
| Pfizer INC. | $15.39 | 2025 | |
| Mylan Specialty L.P. | $14.78 | 2022 | |
| Lilly USA, LLC | $14.34 | 2025 | Zepbound |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Omari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.